We have created a proprietary bispecific IgE antibody platform that allows a single IgE antibody to bind two different antigens simultaneously.
Dual tumour antigen binding can offer a broader spectrum of activity across a treatment population and within an individual patient. The technology can be used with IgE and derivatives such as IgEGs.
